Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
54 hedge funds and large institutions have $64.8M invested in Strongbridge Biopharma plc. in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 13 reducing their positions, and 11 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 58 → 54 (-4)
26% less capital invested
Capital invested by funds: $87.2M → $64.8M (-$22.3M)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.28M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$818K |
| 4 |
BlackRock
New York
|
+$614K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$577K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$4.95M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.75M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$508K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$376K |
| 5 |
Jane Street
New York
|
-$257K |
SBBP Hedge Fund Activity: Q3 2019 in Review
54 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q3 2019, worth a combined $64.8M — down 26% from $87.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SBBP and 7 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 23 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.28M. The largest seller was Armistice Capital, exiting entirely with an estimated $4.95M sold.
- 54 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q3 2019, down from 58 in Q2 2019.
- Funds reported $64.8M of Strongbridge Biopharma plc. stock for Q3 2019, down 26% quarter-over-quarter.
- 7 funds opened new Strongbridge Biopharma plc. positions in Q3 2019 and 11 closed out, a net change of -4 holders.
- The largest Strongbridge Biopharma plc. buyer in Q3 2019 was Point72 Asset Management, an estimated $1.28M added.
- The largest Strongbridge Biopharma plc. seller in Q3 2019 was Armistice Capital, an estimated $4.95M sold.
Based on aggregated 13F filings for Q3 2019.